Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: results from the global noninterventional ETNA-AF program
Event:
EHRA 2021
Topic:
Oral Anticoagulation
Session:
Prevention of stroke in atrial fibrillation